Arcoma AB (ARCOMA) - Net Assets

Latest as of March 2026: Skr75.54 Million SEK ≈ $8.13 Million USD

Based on the latest financial reports, Arcoma AB (ARCOMA) has net assets worth Skr75.54 Million SEK (≈ $8.13 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr101.84 Million ≈ $10.96 Million USD) and total liabilities (Skr26.30 Million ≈ $2.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ARCOMA capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr75.54 Million
% of Total Assets	74.17%
Annual Growth Rate	9.08%
5-Year Change	69.69%
10-Year Change	100.08%
Growth Volatility	64.73

Arcoma AB - Net Assets Trend (2012–2025)

This chart illustrates how Arcoma AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Arcoma AB market cap and net worth.

Annual Net Assets for Arcoma AB (2012–2025)

The table below shows the annual net assets of Arcoma AB from 2012 to 2025. Also explore net asset momentum of Arcoma AB to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	Skr74.73 Million ≈ $8.04 Million	+25.94%
2024-12-31	Skr59.33 Million ≈ $6.39 Million	+21.94%
2023-12-31	Skr48.66 Million ≈ $5.24 Million	+6.06%
2022-12-31	Skr45.88 Million ≈ $4.94 Million	+4.17%
2021-12-31	Skr44.04 Million ≈ $4.74 Million	-11.09%
2020-12-31	Skr49.53 Million ≈ $5.33 Million	+9.62%
2019-12-31	Skr45.19 Million ≈ $4.86 Million	+15.76%
2018-12-31	Skr39.03 Million ≈ $4.20 Million	-4.41%
2017-12-31	Skr40.83 Million ≈ $4.39 Million	+9.33%
2016-12-31	Skr37.35 Million ≈ $4.02 Million	-25.18%
2015-12-31	Skr49.92 Million ≈ $5.37 Million	+19.62%
2014-12-31	Skr41.73 Million ≈ $4.49 Million	+233.32%
2013-12-31	Skr12.52 Million ≈ $1.35 Million	-48.15%
2012-12-31	Skr24.14 Million ≈ $2.60 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Arcoma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr28.62 Million	38.30%
Other Comprehensive Income	Skr42.37 Million	56.69%
Other Components	Skr3.75 Million	5.01%
Total Equity	Skr74.73 Million	100.00%

Arcoma AB Competitors by Market Cap

The table below lists competitors of Arcoma AB ranked by their market capitalization.

Company	Market Cap
Holista Colltech Ltd AU:HCT	$11.71 Million
Sarama Resource V:SWA	$11.72 Million
G.M. LEATHER S.P.A. F:N78	$11.73 Million
Kingsrose Mining Ltd AU:KRM	$11.73 Million
Stavely Minerals Ltd AU:SVY	$11.69 Million
Prospera Energy Inc V:PEI	$11.69 Million
Asturiana de Laminados S.A. MC:ELZ	$11.67 Million
Buxton Resources Ltd AU:BUX	$11.67 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Arcoma AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 59,334,000 to 74,727,000, a change of 15,393,000 (25.9%).
Net income of 5,030,000 contributed positively to equity growth.
New share issuances of 10,362,000 increased equity.
Other comprehensive income increased equity by 13,147,000.
Other factors decreased equity by 13,146,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr5.03 Million	+6.73%
Share Issuances	Skr10.36 Million	+13.87%
Other Comprehensive Income	Skr13.15 Million	+17.59%
Other Changes	Skr-13.15 Million	-17.59%
Total Change	Skr-	25.94%

Book Value vs Market Value Analysis

This analysis compares Arcoma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.46x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 27.29x to 1.46x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	Skr0.28	Skr7.60	x
2013-12-31	Skr0.14	Skr7.60	x
2014-12-31	Skr0.86	Skr7.60	x
2015-12-31	Skr4.80	Skr7.60	x
2016-12-31	Skr3.61	Skr7.60	x
2017-12-31	Skr3.50	Skr7.60	x
2018-12-31	Skr3.09	Skr7.60	x
2019-12-31	Skr3.57	Skr7.60	x
2020-12-31	Skr3.89	Skr7.60	x
2021-12-31	Skr3.40	Skr7.60	x
2022-12-31	Skr3.51	Skr7.60	x
2023-12-31	Skr3.65	Skr7.60	x
2024-12-31	Skr4.50	Skr7.60	x
2025-12-31	Skr5.22	Skr7.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Arcoma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.73%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.85%
• Asset Turnover: 1.35x
• Equity Multiplier: 1.29x
Recent ROE (6.73%) is above the historical average (-10.06%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	-13.36%	-2.19%	2.16x	2.84x	Skr-5.64 Million
2013	-92.85%	-11.47%	1.43x	5.66x	Skr-12.88 Million
2014	2.19%	0.70%	1.65x	1.90x	Skr-3.26 Million
2015	-12.92%	-5.23%	1.46x	1.69x	Skr-11.44 Million
2016	-31.18%	-11.41%	1.43x	1.91x	Skr-15.38 Million
2017	-24.05%	-10.69%	1.35x	1.67x	Skr-13.90 Million
2018	-4.06%	-1.33%	1.57x	1.95x	Skr-5.49 Million
2019	14.63%	4.94%	1.60x	1.84x	Skr2.09 Million
2020	2.76%	1.16%	1.24x	1.92x	Skr-3.59 Million
2021	-16.97%	-6.38%	1.48x	1.80x	Skr-11.88 Million
2022	4.15%	1.52%	1.25x	2.19x	Skr-2.69 Million
2023	5.27%	1.57%	1.99x	1.68x	Skr-2.30 Million
2024	18.84%	7.13%	1.95x	1.36x	Skr5.25 Million
2025	6.73%	3.85%	1.35x	1.29x	Skr-2.44 Million

Industry Comparison

This section compares Arcoma AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $854,447,282
Average return on equity (ROE) among peers: -73.47%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Arcoma AB (ARCOMA)	Skr75.54 Million	-13.36%	0.35x	$11.70 Million
Acarix A/S (ACARIX)	$38.17 Million	-125.99%	0.27x	$26.71 Million
Bactiguard Holding AB (publ) (BACTI-B)	$386.69 Million	4.20%	0.66x	$51.95 Million
BICO Group AB (BICO)	$6.80 Billion	-3.37%	0.43x	$165.40 Million
Boule Diagnostics AB (BOUL)	$169.99 Million	17.80%	0.65x	$10.41 Million
CellaVision AB (CEVI)	$183.52 Million	28.78%	0.20x	$418.90 Million
Clinical Laserthermia Systems AB (publ) (CLS-B)	$43.53 Million	-183.31%	0.33x	$9.40 Million
Chordate Medical Holding AB (CMH)	$29.55 Million	-46.39%	0.39x	$29.05K
C-Rad AB (publ) (CRAD-B)	$29.82 Million	-34.38%	0.50x	$119.27 Million
Duearity AB (DEAR)	$6.06 Million	-318.56%	0.99x	$331.97K

About Arcoma AB

ST:ARCOMA Sweden Medical Devices

Market Cap

$11.70 Million

Skr108.74 Million SEK

Market Cap Rank

#26754 Global

#568 in Sweden

Share Price

Skr7.60

Change (1 day)

-4.52%

52-Week Range

Skr6.92 - Skr9.80

All Time High

Skr25.60